Cargando…

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine

The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-...

Descripción completa

Detalles Bibliográficos
Autores principales: van Westen, Els, Knol, Mirjam J., Wijmenga-Monsuur, Alienke J., Tcherniaeva, Irina, Schouls, Leo M., Sanders, Elisabeth A. M., van Els, Cecile A. C. M., Berbers, Guy A. M., Rots, Nynke Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313931/
https://www.ncbi.nlm.nih.gov/pubmed/30544898
http://dx.doi.org/10.3390/vaccines6040082
_version_ 1783384045297598464
author van Westen, Els
Knol, Mirjam J.
Wijmenga-Monsuur, Alienke J.
Tcherniaeva, Irina
Schouls, Leo M.
Sanders, Elisabeth A. M.
van Els, Cecile A. C. M.
Berbers, Guy A. M.
Rots, Nynke Y.
author_facet van Westen, Els
Knol, Mirjam J.
Wijmenga-Monsuur, Alienke J.
Tcherniaeva, Irina
Schouls, Leo M.
Sanders, Elisabeth A. M.
van Els, Cecile A. C. M.
Berbers, Guy A. M.
Rots, Nynke Y.
author_sort van Westen, Els
collection PubMed
description The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease. We compared the levels of 10-valent (PCV10) and 13-valent (PCV13) pneumococcal vaccine induced serum IgG antibodies at multiple time points after primary vaccinations. Data from two separate studies both performed in the Netherlands in infants vaccinated at 2, 3, and 4 months of age with either PCV10 or PCV13 were compared. Antibody levels were measured at 5, 8, and 11 months of age, during the interval between the primary immunization series and the 11-months booster dose. Serotype-specific IgG levels were determined by multiplex immunoassay. Although antibody kinetics showed significant variation between serotypes and between vaccines for the majority of the 10 shared serotypes, i.e., 1, 5, 7F, 9V, 14, 18C, and 23F, antibody concentrations were sufficiently high for both vaccines, immediately after the primary series and throughout the whole period until the booster dose. In contrast, for serotypes 4 and 19F in the PCV10 group and for serotypes 4 and 6B in the PCV13 group, IgG antibody concentrations already come within reach of the frequently used seroprotection level of 0.35 μg/mL immediately after the primary series at the five month time point and/or at eight months. This paper addresses the importance of revealing differences in serotype-specific and pneumococcal vaccine-dependent IgG antibody patterns during the interval between the primary series and the booster dose, an age period with a high IPD incidence. Trial registration: www.trialregister.nl NTR3069 and NTR2316.
format Online
Article
Text
id pubmed-6313931
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63139312019-01-07 Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine van Westen, Els Knol, Mirjam J. Wijmenga-Monsuur, Alienke J. Tcherniaeva, Irina Schouls, Leo M. Sanders, Elisabeth A. M. van Els, Cecile A. C. M. Berbers, Guy A. M. Rots, Nynke Y. Vaccines (Basel) Article The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease. We compared the levels of 10-valent (PCV10) and 13-valent (PCV13) pneumococcal vaccine induced serum IgG antibodies at multiple time points after primary vaccinations. Data from two separate studies both performed in the Netherlands in infants vaccinated at 2, 3, and 4 months of age with either PCV10 or PCV13 were compared. Antibody levels were measured at 5, 8, and 11 months of age, during the interval between the primary immunization series and the 11-months booster dose. Serotype-specific IgG levels were determined by multiplex immunoassay. Although antibody kinetics showed significant variation between serotypes and between vaccines for the majority of the 10 shared serotypes, i.e., 1, 5, 7F, 9V, 14, 18C, and 23F, antibody concentrations were sufficiently high for both vaccines, immediately after the primary series and throughout the whole period until the booster dose. In contrast, for serotypes 4 and 19F in the PCV10 group and for serotypes 4 and 6B in the PCV13 group, IgG antibody concentrations already come within reach of the frequently used seroprotection level of 0.35 μg/mL immediately after the primary series at the five month time point and/or at eight months. This paper addresses the importance of revealing differences in serotype-specific and pneumococcal vaccine-dependent IgG antibody patterns during the interval between the primary series and the booster dose, an age period with a high IPD incidence. Trial registration: www.trialregister.nl NTR3069 and NTR2316. MDPI 2018-12-11 /pmc/articles/PMC6313931/ /pubmed/30544898 http://dx.doi.org/10.3390/vaccines6040082 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van Westen, Els
Knol, Mirjam J.
Wijmenga-Monsuur, Alienke J.
Tcherniaeva, Irina
Schouls, Leo M.
Sanders, Elisabeth A. M.
van Els, Cecile A. C. M.
Berbers, Guy A. M.
Rots, Nynke Y.
Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title_full Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title_fullStr Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title_full_unstemmed Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title_short Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
title_sort serotype-specific igg antibody waning after pneumococcal conjugate primary series vaccinations with either the 10-valent or the 13-valent vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313931/
https://www.ncbi.nlm.nih.gov/pubmed/30544898
http://dx.doi.org/10.3390/vaccines6040082
work_keys_str_mv AT vanwestenels serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT knolmirjamj serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT wijmengamonsuuralienkej serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT tcherniaevairina serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT schoulsleom serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT sanderselisabetham serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT vanelscecileacm serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT berbersguyam serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine
AT rotsnynkey serotypespecificiggantibodywaningafterpneumococcalconjugateprimaryseriesvaccinationswitheitherthe10valentorthe13valentvaccine